Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study

Highlight

This extensive real-world retrospective cohort study found that concomitant use of sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestin therapy among patients with benign uterine diseases or endometrial hyperplasia (EH) was associated with a significantly lower incidence of endometrial cancer (EC) and fewer subsequent hysterectomies compared to progestin therapy alone.

The hazard ratio for incident EC was 0.43, indicating a 57% risk reduction, and a 49% risk reduction for hysterectomy was observed during a 2-year follow-up period.